Ganglioside treatment in the recovery of the DA nigrostriatal system in different experimental conditions.
D000344:Afferent Pathways / Q000502:physiology; D000818:Animals; D001930:Brain Injuries / Q000473:pathology / Q000503:physiopathology; D002470:Cell Survival; D003342:Corpus Striatum / Q000201:enzymology / Q000502:physiology*; D003714:Denervation; D004298:Dopamine / Q000502:physiology*; D004347:Drug Interactions; D005677:G(M1) Ganglioside / Q000494:pharmacology* / Q000502:physiology; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000502:physiology; D009473:Neuronal Plasticity / Q000187:drug effects*; D051381:Rats; D013378:Substantia Nigra / Q000502:physiology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D005677:G(M1) Ganglioside; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine